MedTrace Logo

Drug-Drug Interaction Potential of Mavorixafor

NCT06914869 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-07-01

No results posted yet for this study

Summary

The main purpose of this study is to evaluate drug-drug interaction (DDI) of orally administered mavorixafor with cytochrome P3A (CYP3A) inducers carbamazepine (a strong CYP3A inducer) or efavirenz (a moderate CYP3A inducer) in healthy male and female participants.

Conditions

  • Healthy Participants

Interventions

DRUG

Mavorixafor

Mavorixafor will be administered per schedule specified in the arm description.

DRUG

Carbamazepine

Carbamazepine will be administered per schedule specified in the arm description.

DRUG

Efavirenz

Efavirenz will be administered per schedule specified in the arm description.

Sponsors & Collaborators

  • X4 Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · X4 Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-18
Primary Completion
2025-05-19
Completion
2025-05-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06914869 on ClinicalTrials.gov